Literature DB >> 25958302

Perinatal Inhibition of NF-KappaB Has Long-Term Antihypertensive and Renoprotective Effects in Fawn-Hooded Hypertensive Rats.

Maarten P Koeners1, Sebastiaan Wesseling2, Manuel Sánchez3, Branko Braam4, Jaap A Joles5.   

Abstract

BACKGROUND: Inhibition of transcription factor nuclear factor-kappa B (NFκB) is beneficial in various models of hypertension and renal disease. We hypothesized first that NFκB inhibition during renal development ameliorates hereditary hypertensive renal disease and next whether this was mediated via suppression of peroxisome proliferator-activated receptor (PPAR)γ coactivator 1α (PGC-1α). METHODS AND
RESULTS: Prior to the development of renal injury in fawn-hooded hypertensive (FHH) rats, a model of hypertension, glomerular hyperfiltration, and progressive renal injury, NFkB activity, measured by nuclear protein expression of NFkB subunit p65, was enhanced twofold in 2-day-old male and female FHH kidneys as compared to normotensive Wistar-Kyoto (WKY) rats (P < 0.05). Treating FHH dams with pyrrolidine di thio carbamate (PDTC), an NFκB inhibitor, from 2 weeks before birth to 4 weeks after birth diminished NFkB activity in 2-day-FHH offspring to 2-day-WKY levels (P < 0.01). Perinatal PDTC reduced systolic blood pressure from 20 weeks onwards by on average 25 mm Hg (P < 0.001) and ameliorated proteinuria (P < 0.05) and glomerulosclerosis (P < 0.05). In kidneys of 2-day-, 2-week-, and adult offspring of PDTC-treated FHH dams, PGC-1α was induced on average by 67% (quantitative polymerase chain reaction (qPCR)) suggesting that suppression of this factor by NFkB could be involved in renal damage. Follow-up experiments with perinatal pioglitazone (Pio), a PPARγ agonist, failed to confer persistent antihypertensive or renoprotective effects.
CONCLUSIONS: Perinatal inhibition of enhanced active renal NFκB in 2-day FHH had persistent antihypertensive and renoprotective effects. However, this was not the case for PPARγ stimulation. NFkB stimulation is therefore involved in renal damage in the FHH model of proteinuric renal disease by pathways other than via PPARγ. © American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  blood pressure; developmental plasticity; glomerulosclerosis; hypertension; nuclear factor-kappa B; renal hemodynamics.

Mesh:

Substances:

Year:  2015        PMID: 25958302     DOI: 10.1093/ajh/hpv065

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

Review 1.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

2.  Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling.

Authors:  Łukasz Bułdak; Grzegorz Machnik; Rafał Jakub Bułdak; Krzysztof Łabuzek; Aleksandra Bołdys; Bogusław Okopień
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-16       Impact factor: 3.000

Review 3.  Reprogramming: A Preventive Strategy in Hypertension Focusing on the Kidney.

Authors:  You-Lin Tain; Jaap A Joles
Journal:  Int J Mol Sci       Date:  2015-12-25       Impact factor: 5.923

Review 4.  PPARs Link Early Life Nutritional Insults to Later Programmed Hypertension and Metabolic Syndrome.

Authors:  You-Lin Tain; Chien-Ning Hsu; Julie Y H Chan
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

Review 5.  Flavonoids as Natural Anti-Inflammatory Agents Targeting Nuclear Factor-Kappa B (NFκB) Signaling in Cardiovascular Diseases: A Mini Review.

Authors:  Ker Woon Choy; Dharmani Murugan; Xin-Fang Leong; Razif Abas; Aspalilah Alias; Mohd Rais Mustafa
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810

Review 6.  Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?

Authors:  You-Lin Tain; Chien-Ning Hsu
Journal:  Int J Mol Sci       Date:  2018-08-31       Impact factor: 5.923

Review 7.  AMP-Activated Protein Kinase as a Reprogramming Strategy for Hypertension and Kidney Disease of Developmental Origin.

Authors:  You-Lin Tain; Chien-Ning Hsu
Journal:  Int J Mol Sci       Date:  2018-06-12       Impact factor: 5.923

8.  APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.

Authors:  Hidefumi Wakashin; Jurgen Heymann; Hila Roshanravan; Parnaz Daneshpajouhnejad; Avi Rosenberg; Myung Kyun Shin; Maarten Hoek; Jeffrey B Kopp
Journal:  BMC Nephrol       Date:  2020-08-27       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.